• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对中位生存时间为 6 个月或更短的非癌症表现的系统回顾。

Systematic review of noncancer presentations with a median survival of 6 months or less.

机构信息

Stanford University School of Medicine, CA, USA.

出版信息

Am J Med. 2012 May;125(5):512.e1-6. doi: 10.1016/j.amjmed.2011.07.028. Epub 2011 Oct 24.

DOI:10.1016/j.amjmed.2011.07.028
PMID:22030293
Abstract

PURPOSE

We report on clinical indicators of 6-month mortality in advanced noncancer illnesses and the effect of treatment on survival.

METHODS

The MEDLINE database was searched comprehensively to find studies evaluating survival for common advanced noncancer illnesses. We retrieved and evaluated studies that reported a median survival of ≤1 year and evaluated prognostic factors or effect of treatment on survival. We extracted data on presentations with median survivals of ≤6 months for heart failure, chronic obstructive pulmonary disease, dementia, geriatric failure to thrive, cirrhosis, and end-stage renal failure. Independent risk factors for survival were combined and included if their combination was associated with a 6-month mortality of ≥50%.

RESULTS

The search identified 1000 potentially relevant studies, of which 475 were retrieved and evaluated, and 74 were included. We report the common clinical presentations that are consistently associated with a 6-month median survival. Even though advanced noncancer syndromes differ clinically, a universal set of prognostic factors signals progression to terminal disease, including poor performance status, advanced age, malnutrition, comorbid illness, organ dysfunction, and hospitalization for acute decompensation. Generally, a 6-month median survival is associated with the presence of 2-4 of these factors. With few exceptions, these terminal presentations are quite refractory to treatment.

CONCLUSION

This systematic review summarizes prognostic factors common to advanced noncancer illness. There is little evidence at present that treatment prolongs survival at these terminal stages.

摘要

目的

本研究报告了晚期非癌症疾病 6 个月死亡率的临床指标,以及治疗对生存率的影响。

方法

全面检索 MEDLINE 数据库,以寻找评估常见晚期非癌症疾病生存率的研究。我们检索并评估了报告中位生存时间≤1 年且评估预后因素或治疗对生存率影响的研究。我们提取了心力衰竭、慢性阻塞性肺疾病、痴呆、老年衰竭、肝硬化和终末期肾病等中位生存时间≤6 个月的表现的数据。将独立的生存风险因素进行合并,如果它们的组合与 6 个月死亡率≥50%相关,则将其包括在内。

结果

搜索确定了 1000 篇潜在相关的研究,其中 475 篇被检索和评估,74 篇被纳入。我们报告了与 6 个月中位生存时间相关的常见临床表现。尽管晚期非癌症综合征在临床上存在差异,但一组普遍的预后因素表明疾病进展到终末期,包括身体状况不佳、年龄较大、营养不良、合并疾病、器官功能障碍和急性失代偿住院治疗。通常,这些因素中有 2-4 个存在与 6 个月中位生存时间相关。除了少数例外,这些终末期表现对治疗的反应相当差。

结论

本系统综述总结了晚期非癌症疾病的常见预后因素。目前几乎没有证据表明治疗能在这些终末期延长生存时间。

相似文献

1
Systematic review of noncancer presentations with a median survival of 6 months or less.对中位生存时间为 6 个月或更短的非癌症表现的系统回顾。
Am J Med. 2012 May;125(5):512.e1-6. doi: 10.1016/j.amjmed.2011.07.028. Epub 2011 Oct 24.
2
Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).纳武单抗用于成人霍奇金淋巴瘤(使用RobotReviewer软件进行的快速综述)
Cochrane Database Syst Rev. 2018 Jul 12;7(7):CD012556. doi: 10.1002/14651858.CD012556.pub2.
3
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
4
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
5
Interventions for fatigue and weight loss in adults with advanced progressive illness.针对患有晚期进行性疾病的成年人疲劳和体重减轻的干预措施。
Cochrane Database Syst Rev. 2012 Jan 18;1:CD008427. doi: 10.1002/14651858.CD008427.pub2.
6
WITHDRAWN: Interventions for fatigue and weight loss in adults with advanced progressive illness.撤回:针对晚期进行性疾病成人患者疲劳和体重减轻的干预措施。
Cochrane Database Syst Rev. 2017 Apr 7;4(4):CD008427. doi: 10.1002/14651858.CD008427.pub3.
7
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.嵌合抗原受体 (CAR) T 细胞疗法治疗复发或难治性弥漫性大 B 细胞淋巴瘤患者。
Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.
8
Incentives for preventing smoking in children and adolescents.预防儿童和青少年吸烟的激励措施。
Cochrane Database Syst Rev. 2017 Jun 6;6(6):CD008645. doi: 10.1002/14651858.CD008645.pub3.
9
What is the value of routinely testing full blood count, electrolytes and urea, and pulmonary function tests before elective surgery in patients with no apparent clinical indication and in subgroups of patients with common comorbidities: a systematic review of the clinical and cost-effective literature.在没有明显临床指征的患者和常见合并症患者亚组中,在择期手术前常规检测全血细胞计数、电解质和尿素以及肺功能测试的价值:对临床和成本效益文献的系统评价。
Health Technol Assess. 2012 Dec;16(50):i-xvi, 1-159. doi: 10.3310/hta16500.
10
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.

引用本文的文献

1
The unwell patient with advanced chronic liver disease: when to use each score?患有晚期慢性肝病的不适患者:何时使用每种评分?
BMC Med. 2025 Jul 9;23(1):413. doi: 10.1186/s12916-025-04185-w.
2
Clinical complications of liver disease in adults after the Fontan operation.Fontan手术后成人肝病的临床并发症
Int J Cardiol Congenit Heart Dis. 2022 Apr 11;8:100371. doi: 10.1016/j.ijcchd.2022.100371. eCollection 2022 Jun.
3
How to deliver palliative care for patients with management in decompensated cirrhosis.如何为失代偿期肝硬化患者提供姑息治疗。
Hepatobiliary Surg Nutr. 2023 Aug 1;12(4):576-579. doi: 10.21037/hbsn-23-222. Epub 2023 Jun 29.
4
Consider hospice in end-stage liver disease prognostic scale to open discussions regarding six-month mortality.在终末期肝病预后量表中考虑临终关怀,以开启关于六个月死亡率的讨论。
JGH Open. 2023 Mar 20;7(4):278-285. doi: 10.1002/jgh3.12889. eCollection 2023 Apr.
5
Quality Versus Quantity of Life: Beyond the Dichotomy.生活质量与生活数量:超越二分法
Palliat Med Rep. 2023 Jan 19;4(1):17-23. doi: 10.1089/pmr.2022.0058. eCollection 2023.
6
A Pilot Study of a Palliative Care Service Embedded in a Hepatology Clinic at a Large Public Hospital.一项在大型公立医院肝病诊所中嵌入姑息治疗服务的初步研究。
J Palliat Med. 2023 Jun;26(6):776-783. doi: 10.1089/jpm.2022.0438. Epub 2022 Dec 26.
7
AASLD Practice Guidance: Palliative care and symptom-based management in decompensated cirrhosis.美国肝病研究学会实践指南:失代偿期肝硬化的姑息治疗与基于症状的管理
Hepatology. 2022 Sep;76(3):819-853. doi: 10.1002/hep.32378. Epub 2022 Apr 22.
8
Longer Walking Distance, More Fat, Better Survival: Prognostic Indicators of Liver Cirrhosis.步行距离更长、脂肪更多、生存状况更佳:肝硬化的预后指标
J Gastrointestin Liver Dis. 2021 Mar 12;30(1):8-12. doi: 10.15403/jgld-3455.
9
Haemorrhagic versus non haemorrhagic ascites in cirrhosis: Their relationship and impact on prognosis of liver cirrhosis.肝硬化患者出血性腹水与非出血性腹水的关系及其对肝硬化预后的影响
Pak J Med Sci. 2020 May-Jun;36(4):603-608. doi: 10.12669/pjms.36.4.2075.
10
Development of a national Department of Veterans Affairs mortality risk prediction model among patients with cirrhosis.退伍军人事务部全国肝硬化患者死亡风险预测模型的开发。
BMJ Open Gastroenterol. 2019 Nov 26;6(1):e000342. doi: 10.1136/bmjgast-2019-000342. eCollection 2019.